A5067298484- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Advancements in Semiconductor Devices and Circuit Design
- Biosimilars and Bioanalytical Methods
- Music Therapy and Health
- Acute Myeloid Leukemia Research
- Nanowire Synthesis and Applications
- Acute Lymphoblastic Leukemia research
- Cancer survivorship and care
- Pain Management and Placebo Effect
- Integrated Circuits and Semiconductor Failure Analysis
- Pediatric Pain Management Techniques
- Virus-based gene therapy research
- Hematopoietic Stem Cell Transplantation
- Childhood Cancer Survivors' Quality of Life
The University of Texas MD Anderson Cancer Center
2019-2023
Texas Woman's University
2022
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 may be associated with long-term adverse effects such as cytopenia and immune deficiency. In order to characterize these late events, we analyzed 31 patients relapsed or refractory large B-cell lymphoma treated axicabtagene ciloleucel at our institution on two clinical trials, ZUMA-1 (clinicaltrials gov. Identifier: NCT02348216) ZUMA-9 NCT03153462). Complete blood counts, lymphocyte subsets, immunoglobulin levels were measured...
7545 Background: Cytopenia lasting beyond 30 days has been observed after CAR T cell therapy. Here, we describe the hematopoietic recovery and immune reconstitution following axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma. Methods: Patients available complete blood counts axi-cel infusion were eligible for analysis. Results: Of 31 treated on ZUMA-1 (=24) ZUMA-9 (=7) trials at our institution, grade ≥3 cytopenias 15 (48%) day (d30), represented by...
Introduction: Cytopenia lasting beyond 30 days has been observed after CAR T cell therapy. Here, we describe the hematopoietic recovery and immune reconstitution following axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma. Methods: Patients available complete blood counts axi-cel infusion were eligible for analysis. Significant cytopenia was defined as any grade 3 or greater hematological toxicity (absolute neutrophil count < 1 x 109/L, hemoglobin 8...
Immunotherapy is a type of treatment that improves an individual’s ability to detect and attack cancerous tissues. The main objective adopting immunotherapy in cancer improve the patient’s quality life (QoL). To address problems faced by patients post immunotherapy, it critical conduct extensive review understand factors impacting QoL patients. Quality concept very relevant discipline nursing. With instrument development population description, oncology nurses have improved theoretical...